INTRODUCTION {#S1}
============

Atopic dermatitis (AD) is a chronic or chronically relapsing inflammatory skin disease. Although the etiology of AD is not completely understood, numerous studies suggest that immune dysregulation and impaired skin barrier function underlie the disease ([@R5]; [@R7]). Epidermal overexpression of thymic stromal lymphopoietin (TSLP), a T~H~2-promoting cytokine ([@R24]; [@R44]), seems to be a major mechanism for AD development ([@R23]; [@R34]; [@R42]). Periostin, an α~v~ integrin-interacting matricellular protein ([@R15]; [@R29]), recently emerged as another mediator for AD that induces TSLP production from keratinocytes ([@R25]). A mouse AD model ([@R35]) induced by epicutaneous treatment of ovalbumin revealed the involvement of T~H~2, T~H~1, and T~H~17 cytokines and other factors ([@R18]). Another model ([@R20]) induced by allergen (extract of *Dermatophagoides farinae*, Der f) and staphylococcal enterotoxin B (SEB) also showed the requirement of mast cells and T cells as well as TSLP receptor (TSLPR) ([@R2]).

Phospholipase C (PLC) is a family of enzymes that catalyze the hydrolysis of phosphatidylinositol 4,5-bisphosphate in order to generate diacylglycerol and inositol 1,4,5-trisphosphate ([@R36]). Independent of its enzymatic activity, PLC-β3 inhibits the proliferation of hematopoietic stem cells (HSCs) and myeloid cells by interacting with SH2-domain-containing protein phosphatase 1 (SHP-1) and signal transducer and activator of transcription 5 (Stat5) and augmenting the dephosphorylating activity of SHP-1 toward Stat5, leading to the inactivation of Stat5 ([@R38]).

The present study demonstrated that PLC-β3-deficient mice spontaneously develop AD-like skin lesions. We investigated the cellular and molecular mechanisms for spontaneous and allergen-induced AD-like dermatitis in *Plcb3^−/−^* mice and their clinical relevance to human AD.

RESULTS {#S2}
=======

PLC-β3-Deficient Mice Spontaneously Develop Mast Cell-Dependent AD-like Dermatitis {#S3}
----------------------------------------------------------------------------------

Young (4- to 10-week-old) *Plcb3^−/−^* mice displayed no obvious abnormalities in their phenotype. By contrast, a majority of older mice developed eczematous skin lesions and hair loss in their periocular areas, cheeks, ears, neck, and trunk ([Figures 1A and 1B](#F1){ref-type="fig"}). The lesions showed hyperkeratosis, thickened epidermis and dermis, and infiltration of T cells, mast cells, macrophages, eosinophils, and neutrophils in the dermis ([Figures 1C and 1D](#F1){ref-type="fig"}). Eczematous *Plcb3^−/−^* mice had high levels of serum immunoglobulin (Ig) E and IgG1, whereas dermatitis-free young *Plcb3^−/−^* mice had low IgE levels ([Figures 1E](#F1){ref-type="fig"} and [S1A](#SD1){ref-type="supplementary-material"}). There was a good correlation between IgE levels and numbers of the involved body parts ([Figure 1F](#F1){ref-type="fig"}). Transepidermal water loss (TEWL) increased only after dermatitis development ([Figure S1B](#SD1){ref-type="supplementary-material"}), suggesting that skin barrier function was not primarily impaired in *Plcb3^−/−^* mice.

No *Plcb3^−/−^;Kit^W-sh/W-sh^* mice (n = 24) deficient in mast cells developed skin lesions during an observation period of 12 months ([Figure 1G](#F1){ref-type="fig"}). By contrast, skin lesions were observed in a majority of αβ T cell-deficient *Plcb3^−/−^* (*Plcb3^−/−^;TCRb^−/−^*) mice and B cell-deficient *Plcb3^−/−^;µMT/µMT* mice. These results suggest that mast cells, but not αβ T or B cells, are indispensable for the spontaneous development of skin lesions in *Plcb3^−/−^* mice.

*Plcb3^−/−^* Mice Develop Severe Allergen-Induced Dermatitis {#S4}
------------------------------------------------------------

Der f/SEB-induced dermatitis is dependent on mast cells and T cells, but not B cells or eosinophils ([@R2]). Epicutaneous treatment with Der f and SEB of young (5- to 11-week-old) *Plcb3^−/−^* mice, which did not show any skin lesions before experiment, induced more severe skin lesions with thicker epidermis and dermis and higher levels of mast cell and neutrophil infiltration, compared to WT mice ([Figures 2A--2E](#F2){ref-type="fig"}). Although Der f/SEB treatment increased serum levels of IgE and IgG1, some of which recognized Der f antigens, their levels were comparable in WT and *Plcb3^−/−^* mice ([Figures S2A and S2B](#SD1){ref-type="supplementary-material"}). As shown previously ([@R2]), mast cell-deficient *Kit^W-sh/W-sh^* mice showed less severe Der f/SEB-induced skin lesions than did WT mice. Mast cell deficiency also resulted in less severe skin lesions in Der f/SEB-treated *Plcb3^−/−^;Kit^W-sh/W-sh^* mice, compared to *Plcb3^−/−^* mice ([Figures 2F and 2G](#F2){ref-type="fig"}). Moreover, engraftment of *Plcb3^−/−^* bone-marrow-derived mast cells (BMMCs) into the back skin of *Plcb3^−/−^;Kit^W-sh/W-sh^* mice restored the severity of Der f/SEB-induced dermatitis to levels in *Plcb3^−/−^* mice ([Figures 2F--2H](#F2){ref-type="fig"}). Therefore, similar to spontaneous dermatitis in *Plcb3^−/−^* mice, mast cells contribute substantially to the development of Der f/SEB-induced dermatitis in these mice. Consistent with increased Der f-specific IgE levels in WT and *Plcb3^−/−^* mice, FcεRI-deficient mice exhibited less severe skin lesions in *FceRIa^−/−^* and *FceRIa^−/−^;Plcb3^−/−^* mice than the respective control FcεRI-sufficient mice ([Figure S2C](#SD1){ref-type="supplementary-material"}). These results indicate that FcεRI is required for full-blown allergen-induced dermatitis.

*Plcb3^−/−^* Mast Cells Are Hypersensitive to Interleukin-3 {#S5}
-----------------------------------------------------------

Mast cells are derived from HSCs via bipotent basophil/mast cell progenitors (BMCPs) and mast cell progenitors (MCPs) ([@R3]; [@R10]). Consistent with the increase in mast cells in the skin and gastrointestinal tract (data not shown), the numbers of BMCPs in spleen and MCPs in bone marrow were increased in young (6- to 10- week-old) *Plcb3^−/−^* mice ([Figure S3A](#SD1){ref-type="supplementary-material"}). Consistent with these in vivo results, 10-fold or more mast cells were generated from bone marrow cells of *Plcb3^−/−^* mice in interleukin (IL)-3-containing medium, compared to WT cells ([Figure 3A](#F3){ref-type="fig"}), although expression levels of FcεRI and c-Kit were similar in both BMMCs ([Figure 3B](#F3){ref-type="fig"}). IL-3-induced proliferation was 2- to 3-fold higher in *Plcb3^−/−^* than in WT BMMCs ([Figure 3C](#F3){ref-type="fig"}), whereas stem cell factor (SCF)-induced proliferation was similar in the two genotypes. *Plcb3^−/−^* BMMCs migrated more vigorously toward IL-3 than WT cells ([Figure 3D](#F3){ref-type="fig"}). On the other hand, growth factor withdrawal induced similar rates of apoptotic cell death in WT and *Plcb3^−/−^* BMMCs (data not shown). These results suggest that the increased proliferation and chemotaxis in response to IL-3 could be the major mechanisms for the increased mast cells in *Plcb3^−/−^* mice. This IL-3 hyperresponsiveness seems due to increased IL-3 receptor (IL-3R) signaling downstream of the receptor, given that expression of IL-3R in mast cells and that of IL-3 mRNA in skin tissues were comparable between WT and *Plcb3^−/−^* mice ([Figures S3B and S3C](#SD1){ref-type="supplementary-material"}).

PLC-β3 Inhibits Stat5 Activity in Mast Cells by Interacting with SHP-1 and Stat5 {#S6}
--------------------------------------------------------------------------------

PLC-β3 interacts with Stat5 and SHP-1 to form the multimolecular SPS complex, and juxtaposition of SHP-1 and Stat5 via interactions with PLC-β3 enhances the catalytic activity of SHP-1 to dephosphorylate Stat5 ([@R38]; [@R41]). As shown for *Plcb3^−/−^* HSCs ([@R38]), IL-3-induced phosphorylation of Stat5 at Tyr^694^, the phosphorylation site critical for its activation ([@R14]), was enhanced in *Plcb3^−/−^* BMMCs ([Figure 3E](#F3){ref-type="fig"}). Furthermore, phosphorylation of SHP-1 at Tyr^536^, which is necessary for efficient interaction with Stat5 ([@R39]), was abolished in *Plcb3^−/−^* cells.

Introduction of dominant-negative Stat5 drastically inhibited proliferation of *Plcb3^−/−^* BMMCs ([Figure 3F](#F3){ref-type="fig"}). Transduction with WT SHP-1 restored SHP-1 phosphorylation and inhibited IL-3-induced Stat5 phosphorylation ([Figure 3G](#F3){ref-type="fig"}) and mast cell proliferation ([Figure 3F](#F3){ref-type="fig"}). These results show that IL-3 hyperresponsiveness caused by PLC-β3 deficiency depends on increased Stat5 activity and reduced SHP-1 activity. Given the comparable expression of IL-3 and IL-3R between WT and *Plcb3^−/−^* mice ([Figures S3B and S3C](#SD1){ref-type="supplementary-material"}), not only IL-3 but also other factors that lead to Stat5 activation would contribute to the increased mast cells in *Plcb3^−/−^* mice.

Stat5 in Mast Cells Is Critical for Full Expression of Allergen-Induced Dermatitis {#S7}
----------------------------------------------------------------------------------

The above results imply that Stat5 and SHP-1 might contribute to dermatitis development by regulating the mast cell responsiveness to IL-3 (and other stimuli). To investigate this possibility more directly, we generated mice with mast cell-specific deletion of *Stat5* (*A* and *B*) or *Shp1* loci, termed *MC*Δ*Stat5* and *MC*Δ*SHP-1* mice, respectively. Loss of expression of the targeted loci was confirmed by immunoblotting of neonatal skinderived mast cells ([Figure 4A](#F4){ref-type="fig"}) and/or immunofluorescence microscopy of skin mast cells ([Figure S4A](#SD1){ref-type="supplementary-material"}). Expression of Cre recombinase driven by the *Mcpt5* promoter ([@R31]) did not affect numbers and distributions of T cells, B cells, or granulocytes (data not shown). Der f/SEB treatment induced significantly lower skin scores in *MC*Δ*Stat5* mice ([Figure 4B](#F4){ref-type="fig"}) with lower infiltration of neutrophils and eosinophils ([Figure 4D](#F4){ref-type="fig"}), but with WT levels of skin thickness ([Figure 4C](#F4){ref-type="fig"}), compared to control mice. By contrast, higher skin scores were observed in *MC*Δ*SHP-1* mice than in control mice ([Figure S4B](#SD1){ref-type="supplementary-material"}). There were similar numbers of mast cells in the ears of WT, *MC*Δ*Stat5* ([Figure 4D](#F4){ref-type="fig"}), and *MC*Δ*SHP-1* mice ([Figure S4C](#SD1){ref-type="supplementary-material"}). Mast cells reactive with phospho-Stat5 antibody were abundant in the inflammatory dermis from Der f/SEB-induced dermatitis ([Figures 4E and 4F](#F4){ref-type="fig"}), although phospho-Stat5 positive cells were not restricted to mast cells. Further confirming the role of Stat5 in skin inflammation, TG101348, an inhibitor of Jak2 kinase that activates Stat5 activity ([@R27]), ameliorated Der f/SEB-induced dermatitis with reduced skin thickness and reduced numbers of mast cells, neutrophils and eosinophils ([Figures S4D--S4F](#SD1){ref-type="supplementary-material"}). These results collectively demonstrate that Stat5 activity in mast cells is required for full expression of allergen-induced skin inflammation.

TSLP Is Highly Expressed in the Epidermis and Critical for Skin Inflammation in *Plcb3^−/−^* Mice {#S8}
-------------------------------------------------------------------------------------------------

Overexpression of TSLP in keratinocytes in transgenic mice results in an AD-like phenotype ([@R23]; [@R42]). TSLP, which activates Stat5 ([@R17]), is highly expressed by keratinocytes in human AD ([@R34]) and, along with IL-1 and TNF, induces mast cells to secrete IL-13, IL-5, and other cytokines ([@R1]). TSLP expression is induced by various stimuli, including allergens, proteases, and mechanical injury ([@R43]). We next examined the role of TSLP in dermatitis in *Plcb3^−/−^* mice. Similar to a report ([@R6]), TSLP protein was highly expressed in the epidermis of lesional skin ([Figure 5A](#F5){ref-type="fig"}), but *TSLP* mRNA levels were not increased in *Plcb3^−/−^* mice (data not shown). As expected, we observed TSLP expression in the epidermis in Der f/SEB-treated *Kit^Wsh/W-sh^* mice and identically treated WT mice. However, TSLP expression was more intense in the thickened epidermis in the latter mice than in the former mice ([Figure S5A](#SD1){ref-type="supplementary-material"}). It was even more exaggerated in Der f/SEB-treated *Plcb3^−/−^* and *Plcb3^−/−^;Kit^W-sh/W-sh^* mice. We interpret that the overexpression of epidermal TSLP in *Plcb3^−/−^* and *Plcb3^−/−^;Kit^W-sh/W-sh^* mice reflects the loss of PLC-β3-mediated suppression of TSLP expression in keratinocytes ([Figure S5B](#SD1){ref-type="supplementary-material"}) in these mice.

Importantly, no *Plcb3^−/−^;TSLPR^−/−^* mice lacking both PLC-β3 and TSLPR (n = 10) developed dermatitis for 12 months ([Figure 5B](#F5){ref-type="fig"}). Consistent with the role of TSLPR in Der f/SEB-induced dermatitis ([@R2]), Der f/SEB-induced dermatitis was less severe in *Plcb3^−/−^;TSLPR^−/−^* mice than in *Plcb3^−/−^* mice ([Figure 5C](#F5){ref-type="fig"}). Lesional skin in the former mice, which exhibited high levels of epidermal TSLP expression (data not shown), had reduced numbers of eosinophils and neutrophils ([Figure 5D](#F5){ref-type="fig"}), but these mice had serum levels of IgE, similar to those of *Plcb3^−/−^* mice (data not shown). TSLP expression was low in Der f/SEB-treated skin of TG101348-treated mice ([Figure S4G](#SD1){ref-type="supplementary-material"}). Therefore, the TSLP-TSLPR axis is critically important for both spontaneous and allergen-induced dermatitis in *Plcb3^−/−^* mice.

Proinflammatory cytokines such as TNF, in combination with T~H~2 cytokines, can induce the expression of TSLP in keratinocytes ([@R6]). However, all *Plcb3^−/−^;TNF^−/−^* mice (n = 34) spontaneously developed dermatitis within 9 months ([Figure 5E](#F5){ref-type="fig"}). Granulocyte macrophage colony stimulating factor (GM-CSF) can also activate Stat5 ([@R26]), promote T~H~2 cell responses ([@R22]), and might contribute to the establishment and chronicity of AD lesions ([@R8]). Although GM-CSF contributed to epidermal and dermal thickening in allergen-induced skin inflammation (T.A. and T.K., unpublished data), all *Plcb3^−/−^;GM-CSF^−/−^* mice (n = 31) spontaneously developed dermatitis within 8 months ([Figure 5F](#F5){ref-type="fig"}). Therefore, both TNF and GM-CSF were dispensable for spontaneous skin inflammation in *Plcb3^−/−^* mice.

PLC-β3 Regulates Periostin Production by Fibroblasts {#S9}
----------------------------------------------------

A recent study showed that periostin is a critical mediator for a Der f-induced AD model and that periostin expression is correlated with the severity of human AD ([@R25]). Periostin was highly expressed in the lesional dermis of spontaneous dermatitis in *Plcb3^−/−^* mice ([Figure 6A](#F6){ref-type="fig"}) as well as Der f/SEB-induced dermatitis in WT and *Plcb3^−/−^* mice ([Figure 6B](#F6){ref-type="fig"}). By contrast, its protein and mRNA expression was reduced in Der f/SEB-induced dermatitis in mast cell-deficient mice ([Figures 6B and 6C](#F6){ref-type="fig"}). Consistent with the known role of periostin in fibrosis, Masson trichrome staining confirmed remarkable fibrosis in skin lesions of spontaneous dermatitis ([Figure S1C](#SD1){ref-type="supplementary-material"}) and Der f/SEB-induced dermatitis (data not shown). To further analyze periostin expression, embryonic fibroblasts (MEFs) and NIH/3T3 fibroblasts were used. When fibroblasts were cocultured with IgE/antigen-stimulated BMMC, periostin secretion was increased ([Figure 6D](#F6){ref-type="fig"}). We confirmed that IL-13, a major cytokine produced by IgE/antigen-stimulated mast cells ([@R9]), enhances the production and secretion of periostin in fibroblasts ([Figure 6E](#F6){ref-type="fig"}). These results collectively demonstrate that mast cells can regulate periostin production in fibroblasts.

Importantly, basal levels of periostin were remarkably higher in *Plcb3^−/−^* than in WT MEFs. Therefore, constitutive expression of periostin appeared to be negatively regulated by PLC-β3. Costimulation of WT, but not *Plcb3^−/−^*, MEFs with TSLP inhibited IL-13-induced periostin production/secretion ([Figure 6F](#F6){ref-type="fig"}). This result suggests the presence of feedback inhibition in the skin for fibroblasts' periostin production by TSLP, which can be induced in keratinocytes by periostin ([@R25]), and this feedback inhibition is lost in *Plcb3^−/−^* MEFs. We also found that TSLP mRNA expression is higher in *Plcb3^−/−^* than in WT keratinocytes ([Figure S5B](#SD1){ref-type="supplementary-material"}), consistent with increased TSLP expression in the epidermis of lesional skin of *Plcb3^−/−^* mice ([Figure 5A](#F5){ref-type="fig"}). These results not only add a cellular component (i.e., mast cells) to the hypothetical vicious cycle of skin inflammation consisting of T~H~2 cytokines (from T~H~2 cells)-periostin (from fibroblasts)-TSLP (from keratinocytes) ([@R25]), but also show that PLC-β3 intrinsically regulates periostin production in fibroblasts and TSLP expression in keratinocytes.

Association of the SPS Complex Genes and Mast Cell-Expressed Phospho-STAT5 with Human AD {#S10}
----------------------------------------------------------------------------------------

The clinical relevance of Der f/SEB-induced dermatitis was supported by similarity in gene expression profiles between this dermatitis and human AD ([@R2]). Gene expression profiles in spontaneous dermatitis in *Plcb3^−/−^* mice were also more similar to those in human AD than those in human psoriasis ([Table S1](#SD1){ref-type="supplementary-material"}). In light of the strong clinical relevance of the two dermatitis models and functional relationship among PLC-β3, STAT5, and SHP-1 in mast cells, we genotyped single nucleotide polymorphisms (SNPs) for these genes ([Table S2](#SD1){ref-type="supplementary-material"}) in AD populations ([Table S3](#SD1){ref-type="supplementary-material"}). The AD patients were stratified as ADEH^+^ and ADEH^−^ based on those who suffered eczema herpeticum and those who did not, respectively. Eczema herpeticum is a severe disseminated herpes virus infection that occurs at skin lesions of AD and other conditions ([@R37]); ADEH^+^ patients suffer more severe dermatitis than ADEH^−^ patients ([@R4]). Among the *PLCB3* SNPs tested, rs2244625 was associated with risk of ADEH in European American subjects ([Table S4](#SD1){ref-type="supplementary-material"}). Furthermore, a nonsynonymous SNP (rs35169799) was significantly associated with decreased levels of IgE among controls but not among AD subjects ([Figure S6A](#SD1){ref-type="supplementary-material"}). [Table S4](#SD1){ref-type="supplementary-material"} shows that *STAT5B* SNP rs9900213 and *SHP1* SNP rs7310161 were significantly associated with the risk of AD among European American subjects. One *STAT5A* SNP (rs16967637) and four *SHP1* SNPs were associated with the severity of AD among African Americans. No AD-associated SNPs except for rs35169799 change protein structures.

Finally, we found that mast cells are more abundant in the dermis of AD lesions than in that of nonlesional skin of AD patients or healthy individuals ([Figures 7A and 7B](#F7){ref-type="fig"}). More importantly, mast cells were abundantly detected with higher nuclear intensities of phospho-STAT5 staining in lesional skin of some AD patients ([Figures 7C--7E](#F7){ref-type="fig"}). Nuclear STAT5 phosphorylation in mast cells was correlated with skin mast cell numbers ([Figure S6B](#SD1){ref-type="supplementary-material"}) and inversely correlated with PLC-β3 expression in mast cells ([Figures S6C--S6F](#SD1){ref-type="supplementary-material"}). The above SNP and immunofluorescence data support the idea that dysregulation of the SPS complex leading to STAT5 activation is involved at least in some cases of human AD.

DISCUSSION {#S11}
==========

In this study, we showed that mast cells, but not αβ T or B cells, are required for spontaneously occurring dermatitis in *Plcb3^−/−^* mice. We show a mast cell-dependent naturally occurring AD model ([@R21]), despite the limitations of Kit mutant mice as a model of mast cell deficiency ([@R28]). *Plcb3^−/−^* mast cells were hyperresponsive to IL-3 due to increased Stat5 activity, which could be antagonized by PLC-β3 and SHP-1. These in vitro results support the in vivo anti-inflammatory role of PLC-β3 and SHP-1 that regulate the proliferative and chemotactic behavior of mast cells by controlling Stat5 activity. Characterization of spontaneous dermatitis in *Plcb3^−/−^* mice was complemented by allergen-induced dermatitis experiments, as the particular importance of Stat5 regulation in mast cells was demonstrated by alleviated allergen-induced dermatitis in mice lacking Stat5 in mast cells and by efficient suppression of allergen-induced dermatitis by chemical inhibition of Stat5 activity. Spontaneous dermatitis in *Plcb3^−/−^* mice depended on the TSLP/TSLPR axis, which uses Stat5 as a critical signal transducer ([@R17]). Thus, Stat5 activation is required for the development of both spontaneous and allergen-induced dermatitis. Human data suggest that STAT5 activating pathways in mast cells are operational in a subset of AD patients.

Various studies suggest the role of T cells in AD pathogenesis ([@R18]; [@R21]). Skin inflammation in our Der f/SEB model requires αβ T cells ([@R2]), in line with the widely accepted scenario for AD development ([@R5]; [@R7]): impaired skin barrier function allows allergens easy access to the inside of skin; allergens are taken up by Langerhans cells and dermal dendritic cells, and these cells migrate and mature to present allergens to naive helper T cells in lymph nodes; activated and differentiated T~H~2 cells migrate back to skin sites re-exposed to allergens; these effector T~H~2 cells recruit mast cells, eosinophils, and other granulocytes in order to cause tissue damages. Although αβ T cells were dispensable for spontaneous dermatitis in *Plcb3^−/−^* mice, αβ T cells seem to contribute to a severe phenotype in this dermatitis. Thus, skin inflammation in *Plcb3^−/−^;TCRβ^−/−^* mice was less prominent than that in *Plcb3^−/−^* mice (data not shown). By contrast, B cells (the source of IgE) appeared to be dispensable for both spontaneous dermatitis and allergen-induced dermatitis, although there was a clear correlation between IgE levels and the severity of dermatitis. This apparent discrepancy seems to be related to the presence of both activating (FcεRI) and inhibitory (FcγRIIb) receptors for IgE in mast cells (and other cells), given that FcεRI was required for maximal allergen-induced skin inflammation.

[@R25] recently proposed a vicious cycle for allergic skin inflammation consisting of T~H~2 cytokines (from T~H~2 cells)-periostin (from fibroblasts)-TSLP and other proinflammatory cytokines (from keratinocytes). Our Der f/SEB induction model requires T cells for full-blown dermatitis, whereas spontaneous and persistent dermatitis in *Plcb3^−/−^* mice does not. The TSLP-TSLPR axis and mast cells are required for both AD models (this study; [@R2]), whereas T cells are required only for allergen-induced dermatitis. Therefore, we speculate that T cells and mast cells are required for TSLP overexpression. Once sustained overexpression of TSLP is established, mast cells may play a more important role in persistent dermatitis as the cellular source of T~H~2 cytokines ([Figure S7](#SD1){ref-type="supplementary-material"}). Related to this network, our current study showed that PLC-β3 can regulate activities of the cellular elements of the network, such as proliferation in mast cells, periostin expression in fibroblasts and TSLP expression in keratinocytes. Our data also suggest the presence of a feedback loop for inhibition of fibroblasts' periostin production by TSLP, and PLC-β3 in fibroblasts is required for this negative feedback. Among the cytokines induced in keratinocytes by periostin, we found that TSLP, but not TNF or GM-CSF, is important for the development of spontaneous dermatitis in *PLC-β3^−/−^* mice.

Our human data are consistent with mouse data by showing genetic linkage with all four genes that encode components of the SPS complex. Although IL-3 alone or IL-3 plus IL-4 cannot induce the differentiation of human mast cells ([@R30]), human mast cells express functional receptors for IL-3, IL-5, and GM-CSF ([@R11]), and, along with SCF, IL-3 can enhance mast cell growth by decreasing mast cell apoptosis ([@R13]). Interestingly, silencing of STAT5A and STAT5B expression induced apoptosis in human mast cells (J.K. and T.K., unpublished data). Thus, the breakdown of PLC-β3/SHP-1-dependent suppression of STAT5 activity, which is recruited by IL-3 or other cytokines in human mast cells, may represent a pathogenic mechanism for human AD. Alternatively, SPS complexes might regulate the growth properties of cell types other than mast cells. Several cytokines including IL-5, IL-21, IL-31, TSLP, and GM-CSF, which are implicated in AD pathogenesis ([@R19]; [@R33]; [@R34]; [@R40]), utilize the JAK-STAT5 pathway for their signal transduction. Reduced expression of PLC-β3, thus improper regulation of STAT5 activity in those cells, would contribute to AD development. These considerations provide additional reasoning for the JAK-STAT5 pathway as a potential target of AD treatment. However, not all AD patients showed increased expression of STAT5 phosphorylation in mast cells. Thus, stratification of AD by STAT5 phosphorylation and/or PLC-β3 expression may be important for clinical application of our results.

EXPERIMENTAL PROCEDURES {#S12}
=======================

Human Subjects {#S13}
--------------

Two independent populations were used for genetic association analysis, including 414 European American subjects and 323 African American subjects. Subjects were recruited as part of the NIAID-supported Atopic Dermatitis and Vaccinia Network (ADVN). Demographic characteristics are presented in [Table S3](#SD1){ref-type="supplementary-material"}. AD patients and healthy individuals were also recruited at University of California San Diego. Skin biopsies using a 4mmpunch biopsy were performed on a lesional target site of atopic skin and a target nonlesional site at least 4 cm from the lesional site. Normal matched control samples were obtained from healthy donors in similar locations.

AD Diagnosis and Phenotypes {#S14}
---------------------------

AD was diagnosed using the US consensus conference criteria ([@R12]). ADEH was defined as AD patients with at least one eczema herpeticum episode documented either by an ADVN investigator or by another physician confirmed by PCR detection of HSV infection, tissue immunofluorescence, Tzanck smear, and/or culture. AD severity was defined according to the "eczema area and severity index" (EASI), a standardized grading system ([@R16]), and total serum IgE was measured using the UniCap 250 system (Pharmacia and Upjohn). Clinical characteristics are presented in [Table S3](#SD1){ref-type="supplementary-material"}. The study was approved by the institutional review boards at National Jewish Health in Denver, Johns Hopkins University, Oregon Health and Science University, University of California San Diego, Children's Hospital of Boston, and University of Rochester. All subjects gave written informed consent prior to participation.

Genotyping and Quality Control {#S15}
------------------------------

A total of 22 SNPs for the four candidate genes were selected from the HapMap (<http://www.hapmap.org/>) using a tagging approach: eight *PLCb3* SNPs, six *STAT5A* SNPs, four *STAT5B* SNPs, and four *SHP1* SNPs. The four SNPs in *STAT5B* were genotyped using the custom-designed Illumina OPA for the BeadXpress Reader System and the GoldenGate Assay with VeraCode Bead technology according to the manufacturer's protocol. The rest of SNPs were genotyped and analyzed on a 7900HT Sequence Detection System (Applied Biosystems) with Applied Biosystems Genotyper software (SDS system, version 2.2). As part of quality control, we genotyped additional 74 SNPs identified as ancestry informative markers selected for maximal difference between African and European populations and assessed potential confounding factors due to population substructure using genotype data and the STRUCTURE program (v.2.2; <http://pritch.bsd.uchicago.edu/software>).

Mice {#S16}
----

*Plcb3^−/−^* mice were backcrossed to C57BL/6 mice for 12 generations. C57BL/6-*Kit^W-sh/W-sh^* mice were bred to *Plcb3^−/−^* mice, and their F1 mice were intercrossed to generate mast cell-deficient *Kit^W-sh/W-sh^;Plcb3^−/−^* mice. Other double-mutant mice were similarly generated. Dermatitis in both male and female mice under SPF conditions was scored by gross appearance and confirmed by histology. Animal experiments were approved by the Animal Use and Care Committee of the La Jolla Institute for Allergy and Immunology (LIAI) and carried out in the LIAI animal facility.

Mast Cell Engraftment {#S17}
---------------------

BMMCs derived from female *Plcb3^−/−^* mice were transferred by intradermal injection (4 × 10^6^ cells in 50 µl DMEM per site, totally 20 sites distributed in five rows down the length of shaved back skin) into 4-week-old female *Plcb3^−/−^;Kit^W-sh/W-sh^* mice.

Der f/SEB Induction of AD-like Skin Lesions {#S18}
-------------------------------------------

AD-like skin lesions were induced by two rounds of epicutaneous treatment of shaved back skin of male mice with Der f and SEB as described ([@R20]). AD scores are based on the severity (0, no symptoms; 1, mild; 2, intermediate; 3, severe) of four possible symptoms (redness, bleeding, eruption, and scaling). A scientist who did not know the identities of mice scored skin lesions.

Cultures of Mast Cells and Retroviral Transduction {#S19}
--------------------------------------------------

Bone marrow cells or MCPs purified by fluorescence-activated cell sorting (FACS) ([@R10]) were cultured in IL-3-containing medium. Live cells were counted during weekly media changes. Recombinant retroviruses were generated by transfection of Plat-E cells with pMIG vectors. Bone marrow cells or MCPs were infected with the retroviruses, and GFP^+^ cells were FACS purified and cultured.

Neonatal Skin-Derived Mast Cells {#S20}
--------------------------------

Newborn skin was incubated with 0.5% trypsin-EDTA (Invitrogen) for 1 hr, and epidermis was removed. Separated dermis was minced and incubated in DMEM containing 2 U/mL of Liberase TL (Roche Applied Science) and 1.6 mg/ml of hyaluronidase (Sigma-Aldrich). Dispersed cells were cultured in RPMI1640 supplemented with 10% FCS, IL-3, and SCF. FcεRIα^+^ c-Kit^+^ cells were sorted and subject to immunoblot analysis.

Microarray Analysis of Gene Expression {#S21}
--------------------------------------

RNA preparation, microarrays, and data analysis were described previously ([@R2]). Data have been deposited in the NCBI Gene Expression Omnibus under accession number GSE53132.

Histology {#S22}
---------

Skin biopsies were fixed with 10% formaldehyde and embedded in paraffin. Sections were stained with hematoxylin and eosin staining (H&E), Toluidine blue, Congo-red, or Masson trichrome. For immunohistochemistry, skin biopsies were immediately embedded in O.C.T. compound (Sakura Tissue- Tek) and stored at −80°C. Cryosections were fixed, and endogenous peroxidase was quenched with 3% H~2~O~2~ in cold methanol. ABC Staining Systems (Santa Cruz Biotechnology) were used to visualize stainings with anti-CD4 (Santa Cruz), anti-CD8 (BD Biosciences), or anti-Mac-1 (BD Biosciences) as primary antibodies. For immunofluorescence, biopsies were fixed in 4% paraformaldehyde at 4°C, washed in 10%--20% sucrose in phosphate buffered saline, embedded in O.C.T. compound, and stored at −80°C. Cryosections were dried, rehydrated, and incubated with anti-CD4, anti-CD8, anti-F4/80 (Abcam), or anti-TSLP (Amgen) at 4°C overnight. After washing, sections were incubated with Texas-red-conjugated goat anti-rat IgG (Southern Biotech), and mounted with ProLong Gold antifade reagent with DAPI (Invitrogen). For the detection of periostin and phospho-Stat5 in mast cells, 10% formalin-fixed sections were subjected to heat-induced antigen retrieval after deparaffinization. Antiperiostin ([@R25]), anti-phospho-Stat5 (Abcam), anti-mast cell tryptase (Abcam), or anti-mMCP4 and anti-mMCP6 ([@R32]) was used as a primary antibody, in combination with Alexa-Fluor-488-, -568-, or -647-conjugated goat anti-mouse, antirat, or anti-rabbit antibody (Invitrogen) as a secondary antibody. Fluorescent images were observed at the magnification of 400 under either Nikon Eclipse 80i fluorescence microscope or Olympus FluoView FV10i confocal laser microscope. Human skin mast cells were counted (\>100 per sample) in rectangular regions covering the entire skin layers from the epidermis to subcutaneous adipose tissues.

Flow cytometry {#S23}
--------------

Expression of c-Kit, FcεRI, and IL-3 receptor on mast cells was analyzed using FACSCalibur (BD Biosciences) after staining with APC-conjugated anti-c-Kit (2B8, BD Biosciences), FITC-conjugated anti-FcεRI (MAR-1, BioLegend), or PE-conjugated anti-iL-3 receptor (5B11, BD Biosciences).

Immunoblotting {#S24}
--------------

Mast cells were stimulated with IL-3 and lysed in 1% NP-40 lysis buffer. Lysates were analyzed by SDS-PAGE followed by electroblotting to PVDF membranes (Millipore). Membranes were incubated with a primary antibody and then with an HRP-conjugated secondary antibody. Antibody-bound proteins were revealed by ECL reagent (PerkinElmer).

Statistical Analysis {#S25}
--------------------

For genetic analysis, logistic regression, adjusting for the first two principal components, was used to test for association between each individual marker (under an additive model) and disease status using PLINK software (<http://pngu.mgh.harford.edu/~purcell/plink/to>). To test for association between genetic markers and total serum levels of log-adjusted IgE and log-adjusted EASI score, we used linear regression models adjusting for confounding variables age and gender as well as the first two principal components. Departures from Hardy-Weinberg equilibrium at each locus were tested with chi-square tests separately for cases and controls using PLINK. Other statistical analyses are performed by Student's t test, ANOVA, or Tukey's test as shown.

Supplementary Material {#SM}
======================

**ACCESSION NUMBERS**

Microarray data have been deposited in the NCBI Gene Expression Omnibus under accession number GSE53132.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Supplemental Experimental Procedures, seven figures, and four tables and can be found with this article online at <http://dx.doi.org/10.1016/j.celrep.2013.12.029>.
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![*Plcb3^−/−^* Mice Spontaneously Develop AD-like Skin Lesions in a Mast Cell-Dependent Manner\
(A) Kaplan-Meier plots for dermatitis development in *Plcb3^−/−^* mice (n = 21).\
(B) Note the eczematous skin lesions and hair loss in periocular areas, cheeks, ears, neck, and flanks in a 10-month-old *Plcb3^−/−^* mouse.\
(C) Histology of healthy (WT) and skin lesions (*Plcb3^−/−^*) in ear. Scale bar, 100 µm.\
(D) Graphic representation of histological analysis of ear skin lesions of 8- to 10-month-old WT and *Plcb3^−/−^* mice. Neutrophils (Neut), eosinophils (Eos), and mast cells (MC) were enumerated in H&E-, Congo-red- and Toluidine-blue-stained preparations, respectively. Immunofluorescence staining was performed to detect CD4^+^, CD8^+^, and F4/80^+^ (Mϕ) cells. Data represent mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 versus WT mice by Student's t test. Similar results were obtained in lesional skin in cheeks and neck (data not shown). HPF, high-power field.\
(E) Serum IgE levels were increased in 8- to 10-month-old *Plcb3^−/−^* mice. Data represent mean ± SEM.\
(F) Correlation between serum IgE levels and numbers of body parts with skin lesions (see the legend for B for eczematous body parts). r^2^ = 0.78, p \< 0.0001, Pearson's correlation.\
(G) Incidence of skin lesions in *Plcb3^−/−^* (KO), *Plcb3^−/−^;Kit^W-sh/W-sh^* (KO;W^sh^), *Plcb3^−/−^;TCRb^−/−^* (*KO;TCRb*^−^) and *Plcb3^−/−^;µMT/µMT* (*KO;µMT*) mice for 12 months.\
Results in (E) and (F) are representative of two independent experiments using three to six mice per group. See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms552005f1){#F1}

![Mast Cells Significantly Contribute to the Increased Severity of Der f/SEB-Induced Skin Lesions in *Plcb3^−/−^* Mice\
(A) AD-like skin lesions were induced as described previously ([@R20]). D/B, treatment with Der f and SEB. The periods when Der f/SEB-treated back skin is occluded with Tegaderm are also shown.\
(B) AD scores on day 24 with WT and *Plcb3^−/−^* mice.\
(C) H&E staining of lesional skins in WT and *Plcb3^−/−^* (KO) mice.\
(D) Thicknesses of epidermis and dermis at basal and Der f/SEB (D/B)-treated levels were measured on H&E-stained lesional skins. Results in (B)--(D) are representative of three independent experiments using five to eight mice per group.\
(E) Histologic analysis of Der f/SEB-induced dermatitis.\
(F and G) Dermatitis was induced in WT, *Kit*^W-sh/W-sh^ (Wsh), *Plcb3^−/−^* (KO) and *Plcb3^−/−^;Kit*^W-sh/W-sh^ (KO;Wsh) mice. A group of *Plcb3^−/−^;Kit*^W-sh/W-sh^ mice received BMMCs derived from *Plcb3^−/−^* mice 6 weeks before Der f/SEB treatment. (F) AD scores on day 24. (G) Histologic analysis of dermatitis. Data represent mean ± SD. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 versus WT mice or indicated pairs by Student's t test or ANOVA; \#\#, p \< 0.01 versus naive mice.\
(H) Mast cells were quantified on Toluidine-blue-stained skin tissues. HPF, high-power field.\
Results in (F)--(H) are representative of two independent experiments using six mice per group. See also [Figure S2](#SD1){ref-type="supplementary-material"}.](nihms552005f2){#F2}

![*Plcb3^−/−^* Mast Cells Are Hypersensitive to IL-3 Stimulation\
(A) Bone marrow cells derived from WT or *Plcb3^−/−^* mice were cultured in IL-3-containing medium for the indicated periods. Live cells were counted.\
(B) Greater than 98% of 5 week cultured BMMCs expressed c-Kit and FcεRI. Results in (A) and (B) are representative of at least ten experiments using three to four mice per group.\
(C) BMMCs were depleted of IL-3 for 8 hr and cultured in the indicated concentrations of IL-3 or SCF for 36 hr. DNA synthesis was measured by \[^3^H\]thymidine incorporation during the last 18 hr of culture.\
(D) Chemotaxis of BMMCs toward IL-3 or SCF was assayed in Transwell for 8 hr. Results in (C) and (D) are representative of two experiments using three mice per group.\
(E) WT and *Plcb3^−/−^* BMMCs were stimulated with 10 ng/ml of IL-3 for the indicated periods. Cell lysates were analyzed by SDS-PAGE followed by western blotting using antibodies for the indicated molecules.\
(F and G) WT and *Plcb3^−/−^* MCPs were transduced with bicistronic retroviral vectors coding for DN Stat5 (DN5), WT SHP-1, or empty vector. GFP^+^-transduced cells were FACS-sorted and cultured in IL-3 (F). \*p \< 0.05 versus empty vector-transduced WT cells (WT \[vec\]) by Student's t test. Some transduced *Plcb3^−/−^* mast cells were stimulated with IL-3 and subjected to western blot analysis (G).\
Results in (E)--(G) are representative of two transduction experiments. In (A), (C), (D), and (F), data represent mean ± SEM. See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms552005f3){#F3}

![Stat5 in Mast Cells Regulates Der f/SEB-Induced Dermatitis\
Dermatitis was induced with Der f/SEB in *MC*Δ*Stat5* mice \[CKO or Cre(^+^)\] and their floxed control \[fl/fl or Cre(^−^)\] mice. \*p \< 0.05, \*\*\*p \< 0.001 by Student's t test.\
(A) Western blot analysis of Stat5 in mast cells derived from neonatal skin of *MC*Δ*Stat5* (CKO) and control (fl/fl) mice.\
(B) AD scores accumulated from four separate experiments using three to five mice per group.\
(C) Thicknesses of epidermis and dermis after Der f/SEB (D/B) treatment.\
(D) Histologic analysis of Der f/SEB-induced dermatitis. Data represent mean ± SEM.\
(E and F) Skin sections of naive and Der f/SEB-induced (6 hr after fourth induction) dermatitis in WT mice were stained for phospho-Stat5, mMCP4, and mMCP6. Arrowheads indicate pStat5-positive mast cells. Ep, epidermis; D, dermis; HF, hair follicle. Representative images of mast cells from three experiments are shown in (E) and (F). See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms552005f4){#F4}

![Role of the TSLP-TSLPR Axis in Der f/SEB-Induced Dermatitis and Spontaneous Dermatitis in *Plcb3^−/−^* Mice\
(A) Lesional skin from 10-month-old *Plcb3^−/−^* mice and healthy control (WT) were stained for TSLP (red) and nuclei (blue).\
(B) Kaplan-Meier plots for dermatitis development in *Plcb3^−/−^;TSLPR^−/−^* (n = 10).\
(C) Dermatitis was induced with Der f/SEB in WT, *TSLPR*^−/−^ (T^−/−^), *Plcb3^−/−^* (b3^−/−^), and *Plcb3^−/−^;TSLPR^−/−^* (b3^−/−^;T^−/−^) mice.\
(D) Histologic analysis of Der f/SEB-induced dermatitis. Data represent mean ± SEM.\
(E and F) Kaplan-Meier plots for dermatitis development in *Plcb3^−/−^;TNF^−/−^* (n = 34), and *Plcb3^−/−^;GM-CSF^−/−^* (n = 31) mice.\
Results in (C) and (D) are representative of two independent experiments using three to six mice per group. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 by ANOVA. See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms552005f5){#F5}

![Regulation of Periostin Production in Fibroblasts\
(A) Lesional skin of spontaneous dermatitis in *Plcb3^−/−^* mice (KO) and normal skin from WT mice (WT) were stained for periostin (red) and nuclei (blue). Right panels show control stainings without antiperiostin antibody.\
(B) Periostin was stained before (naive) and after Der f/SEB induction of dermatitis (induced) in WT, *Kit*^W-sh/W-sh^ (Wsh), *Plcb3^−/−^* (KO), and *Plcb3^−/−^;Kit*^W-sh/W-sh^ (KO;W^sh^) mice. Borders of epidermis, dermis and subcutaneous fat tissues are indicated by dotted lines.\
(C) Periostin mRNA expression in Der f/SEB-treated skin was quantified by qPCR.\
(D) NIH/3T3 cells were incubated with or without IgE-sensitized BMMCs in the presence or absence of antigen.\
(E and F) WT and *Plcb3^−/−^* MEFs were stimulated by the indicated concentrations of IL-13 in the absence (E) or presence (F) of 0, 10, or 100 ng/ml of TSLP for 24 hr.\
Results in (A)--(C) are representative of three experiments using three to five mice per group. Periostin protein in culture supernatants and lysates of the cells was analyzed by western blotting. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 by ANOVA. In vitro experiments with results similar to (D)--(F) were performed two to four times. See also [Figure S7](#SD1){ref-type="supplementary-material"}.](nihms552005f6){#F6}

![Increased Numbers of Mast Cells with Enhanced STAT5 Phosphorylation in Human AD Patients\
(A) Lesional and nonlesional skin samples of human AD patients were analyzed by Toluidine blue staining. Portions indicated by rectangle are enlarged on right panels. Red arrows indicate mast cells.\
(B) Quantification of mast cells. \*\*p \< 0.01; \*\*\*p \< 0.001 by Tukey's multiple comparison test (ANOVA).\
(C) Skin samples of human AD patients were stained for phospho-STAT5 (red), tryptase (green), and nuclei (blue). Representative images are shown from patient P1.\
(D and E) Nuclear phospho-STAT5 levels in mast cells in lesional (L) and nonlesional (NL) skin samples of human AD patients and healthy skin\
(H) were measured by ImageJ software (NIH). Data represent mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 versus nonlesional (NL) skin by Student's t test. See also [Figure S6 and Tables S1--S4](#SD1){ref-type="supplementary-material"}.](nihms552005f7){#F7}
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